palmitoylethanolamide.com.au
HomeResearchMarco 2021

Effectiveness of Nonpharmacologic Treatments of Burning Mouth Syndrome: A Systematic Review

Marco Cabras, Alessio Gambino, Roberto Broccoletti, Simona De Paola, Savino Sciascia, Paolo G Arduino. J Oral Facial Pain Headache. 2021;35(3):175-198.

ReviewHumans

Design
Review
Subjects
27 randomised controlled trials and 6 open clinical trials covering 14 non-pharmacological interventions
Dose used in the study
Alpha-lipoic acid 600 to 800 mg/day in 11 trials; palmitoylethanolamide dose not stated
Duration
Alpha-lipoic acid 30 to 120 days; capsaicin 7 to 30 days; PEA duration not stated
What was measured
Pain relief and other outcomes of non-pharmacological treatments for burning mouth syndrome, with risk of bias assessment.

What the authors reported

This review of burning mouth syndrome treatments found:

  • Seven placebo-controlled alpha-lipoic acid trials showed significant pain relief.
  • Two capsaicin trials and four of five acupuncture trials were favourable.
  • Short-term pain relief was reported in single placebo-controlled trials of tocopherol, catuama, ultramicronised palmitoylethanolamide, psychotherapy, cognitive therapy and rTMS.
  • Most therapies were reported as safe.

Limits of this study

The authors rate the evidence as highly biased, short-term and heterogeneous. Ultramicronised palmitoylethanolamide was supported by one trial only, described as anecdotal, with no numbers given. Funding and conflicts not stated in the abstract.

Source

PubMed 34609377 · doi:10.11607/ofph.2868

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.